#United States #San Diego #Inhibrx #ozekibart #INBRX-106

Inhibrx Biosciences Reports Q2 2026 Financial Results

Inhibrx Biosciences, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company, has disclosed its financial performance for the second quarter of 2026. With innovative programs under development, the company is actively progressing its research and clinical trials in the biopharma space.

Corporate Highlights and Developments

The second quarter reflected significant corporate activities and milestones for Inhibrx. One of the notable achievements was the amendment of the Loan and Security Agreement with Oxford Finance LLC, resulting in an additional $325 million of funding. This infusion includes $100 million that was made available upon the agreement's execution, with the balance to be drawn at the company’s discretion based on defined milestones.

In terms of clinical progress, Inhibrx is focusing on two prominent programs: INBRX-106 and Ozekibart (INBRX-109). The former's randomized Phase 2 trial, which evaluates its effectiveness in head and neck squamous cell carcinoma (HNSCC) in conjunction with pembrolizumab, is expected to release progression-free survival (PFS) data by Q3 2026. Meanwhile, Ozekibart has seen expanded Phase 1 cohorts initiated for colorectal cancer (CRC), assessing its combined effectiveness with therapies such as Folfiri, Avastin, and Lonsurf. Interim results from these trials are anticipated in Q1 2027.

Additionally, the U.S. Food and Drug Administration’s (FDA) acceptance of Inhibrx’s biologics license application (BLA) for Ozekibart, targeting conventional chondrosarcoma, set a Prescription Drug User Fee Act (PDUFA) goal date for April 14, 2027. This regulatory milestone marks a pivotal step towards potential approval.

Financial Overview

As of June 30, 2026, Inhibrx reported cash and cash equivalents totaling $133.3 million, an increase to $219.5 million as of August 6, 2026, reflecting the successful funding from the amended loan agreement. The revenue for Q2 2026 remained at $0, contrasting with $1.3 million earned during the same period in the previous year.

Research and development expenditures surged to $23.9 million for Q2 2026, up from $22.3 million in Q2 2025, driven mainly by escalating clinical trial costs and initial stages of manufacturing for its BLA filing of Ozekibart. This increase highlights Inhibrx’s commitment to advancing its clinical programs despite facing financial challenges.

The general and administrative expenses also rose, from $6.4 million in Q2 2025 to $8.3 million in Q2 2026, largely due to pre-commercialization efforts aimed at market access and product launch preparation for Ozekibart.

As for profitability, the company faced a net loss of $36.7 million in Q2 2026, which translates to a loss per share of $2.34, widening compared to the previous year’s loss of $28.7 million, or $1.85 per share.

Strategic Outlook

Inhibrx's strategy involves capitalizing on its advanced pipeline of therapeutic candidates while navigating the complexities of clinical development. The company has demonstrated resilience through its ongoing engagements with the FDA, and anticipates discussions in late 2026 regarding trial registrations and potential accelerated approval pathways for its products.

In conclusion, Inhibrx is at a crucial juncture in its corporate journey, marked by promising clinical data, strategic funding initiatives, and a resilient approach to regulatory dealings. Investors and stakeholders will be keenly observing how these developments unfold as they prepare for significant announcements in the upcoming quarters. For a more detailed view of Inhibrx’s pipeline and corporate strategies, please visit their official website.